Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
Friday, December 22, 2006 BiopharmaWatch Research 1 min read
Key Takeaway: Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody.